NASDAQ:GLSI Greenwich LifeSciences (GLSI) Stock Forecast, Price & News $10.97 +0.30 (+2.81%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$10.31▼$11.0450-Day Range$10.35▼$14.1152-Week Range$6.82▼$21.50Volume47,710 shsAverage Volume17,001 shsMarket Capitalization$140.96 millionP/E RatioN/ADividend YieldN/APrice Target$38.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Greenwich LifeSciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside246.4% Upside$38.00 Price TargetShort InterestHealthy6.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$126,002 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector599th out of 983 stocksPharmaceutical Preparations Industry298th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingGreenwich LifeSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.00, Greenwich LifeSciences has a forecasted upside of 246.4% from its current price of $10.97.Amount of Analyst CoverageGreenwich LifeSciences has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.76% of the float of Greenwich LifeSciences has been sold short.Short Interest Ratio / Days to CoverGreenwich LifeSciences has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Greenwich LifeSciences has recently decreased by 21.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGreenwich LifeSciences does not currently pay a dividend.Dividend GrowthGreenwich LifeSciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLSI. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 1 people have searched for GLSI on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat Follows4 people have added Greenwich LifeSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Greenwich LifeSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $126,002.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders52.14% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.18% of the stock of Greenwich LifeSciences is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioGreenwich LifeSciences has a P/B Ratio of 12.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Greenwich LifeSciences (NASDAQ:GLSI) StockGreenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Read More Receive GLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address GLSI Stock News HeadlinesMay 20, 2023 | americanbankingnews.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Purchases 1,000 SharesApril 22, 2023 | americanbankingnews.comSnehal Patel Acquires 2,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) StockJune 3, 2023 | Behind the Markets (Ad)How A.I. Could Make Most 21st Century Diseases EXTINCTOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...April 19, 2023 | usnews.comEast Greenwich High SchoolApril 19, 2023 | usnews.comGreenwich Junior-Senior High SchoolApril 19, 2023 | americanbankingnews.comShort Interest in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Increases By 43.2%April 13, 2023 | americanbankingnews.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson Acquires 1,000 SharesApril 13, 2023 | americanbankingnews.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Acquires 5,000 Shares of StockJune 3, 2023 | Behind the Markets (Ad)WARNING to all American InvestorsChina's sneaky plan could wipe out your retirement - in a single morning. Learn how to protect yourself here>>>April 12, 2023 | greenwichtime.comIn Photos: Greenwich turns out for an Easter Egg Hunt and festival courtesy of the Historical SocietyApril 12, 2023 | americanbankingnews.comHC Wainwright Trims Greenwich LifeSciences (NASDAQ:GLSI) Target Price to $38.00April 10, 2023 | msn.comHC Wainwright & Co. Reiterates Greenwich Lifesciences (GLSI) Buy RecommendationApril 10, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Greenwich LifeSciences (GLSI)April 9, 2023 | greenwichtime.comGreenwich BET OKs $482M budget: Rink replacement money, yes; Cos Cob Library renovation, noApril 9, 2023 | greenwichtime.comFlorida man now second person arrested in $64K email scam targeting Greenwich womanApril 8, 2023 | greenwichtime.comStamford man accused of 2021 Greenwich sexual assault expected to make plea in May, police sayApril 6, 2023 | finance.yahoo.comInsiders own 39% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares but retail investors control 42% of the companyApril 2, 2023 | greenwichtime.comGreenwich Hospital raises $4 million for behavioral health expansionApril 1, 2023 | greenwichtime.comParents, others tell Greenwich BET there's 'no rationale for the nickel and diming' on school projectsMarch 20, 2023 | greenwichtime.comGreenwich High's long-debated $3.3 million entryway vestibule project OKed by school boardMarch 19, 2023 | greenwichtime.comIn Photos: Greenwich Public Schools students' art featured at Bendheim GalleryMarch 19, 2023 | greenwichtime.comExpanded clubhouse proposed at Greenwich apartment complex once target of lawsuitMarch 17, 2023 | greenwichtime.comFamily mourns Greenwich pedestrian who died after being struck by a car as devoted mother, dog loverMarch 12, 2023 | greenwichtime.comGreenwich man turns lost story by 'Black Adam' co-creator and 'Superman' writer into graphic novelMarch 12, 2023 | greenwichtime.comGreenwich registrars (opinion): There is nothing 'lurking underneath' the grantMarch 7, 2023 | greenwichtime.comOpinion: Why we can’t have nice things in GreenwichMarch 4, 2023 | greenwichtime.comGreenwich officials spar over new Central Middle School price during budget talksSee More Headlines GLSI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLSI Company Calendar Today6/03/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLSI CUSIPN/A CIK1799788 Webwww.greenwichlifesciences.com Phone832-819-3232FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Forecast$38.00 High Stock Price Forecast$38.00 Low Stock Price Forecast$38.00 Forecasted Upside/Downside+246.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.73% Return on Assets-54.81% Debt Debt-to-Equity RatioN/A Current Ratio50.47 Quick Ratio50.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.91 per share Price / Book12.05Miscellaneous Outstanding Shares12,850,000Free Float6,149,000Market Cap$140.96 million OptionableNot Optionable Beta0.89 Key ExecutivesMr. Snehal S. Patel (Age 60)CEO, CFO & Director Comp: $925kMr. Eric Rothe (Age 48)Founder & Independent Director Dr. Frank Joseph Daugherty M.D. (Age 73)Chief Medical Officer & Director Dr. Jaye L. Thompson Ph.D. (Age 57)VP of Clinical & Regulatory Affairs Dr. Christine T. Fischette Ph.D. (Age 72)VP of Bus. Devel. Key CompetitorsEvofem BiosciencesNASDAQ:EVFMOptiNoseNASDAQ:OPTNProQR TherapeuticsNASDAQ:PRQRHeron TherapeuticsNASDAQ:HRTXCorvus PharmaceuticalsNASDAQ:CRVSView All CompetitorsInsiders & InstitutionsSnehal PatelBought 1,000 shares on 5/17/2023Total: $11,690.00 ($11.69/share)Susquehanna International Group LLPBought 37,100 shares on 5/16/2023Ownership: 0.289%Jane Street Group LLCBought 18,510 shares on 5/16/2023Ownership: 0.144%BlackRock Inc.Bought 5,830 shares on 5/12/2023Ownership: 0.442%Renaissance Technologies LLCBought 17,500 shares on 5/12/2023Ownership: 0.395%View All Insider TransactionsView All Institutional Transactions GLSI Stock - Frequently Asked Questions Should I buy or sell Greenwich LifeSciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Greenwich LifeSciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLSI shares. View GLSI analyst ratings or view top-rated stocks. What is Greenwich LifeSciences' stock price forecast for 2023? 1 Wall Street research analysts have issued 12 month price targets for Greenwich LifeSciences' shares. Their GLSI share price forecasts range from $38.00 to $38.00. On average, they anticipate the company's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 246.4% from the stock's current price. View analysts price targets for GLSI or view top-rated stocks among Wall Street analysts. How have GLSI shares performed in 2023? Greenwich LifeSciences' stock was trading at $15.20 at the start of the year. Since then, GLSI shares have decreased by 27.8% and is now trading at $10.97. View the best growth stocks for 2023 here. When is Greenwich LifeSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our GLSI earnings forecast. When did Greenwich LifeSciences IPO? (GLSI) raised $7 million in an initial public offering on Friday, September 25th 2020. The company issued 1,300,000 shares at $5.75 per share. Aegis Capital acted as the underwriter for the IPO. What is Greenwich LifeSciences' stock symbol? Greenwich LifeSciences trades on the NASDAQ under the ticker symbol "GLSI." Who are Greenwich LifeSciences' major shareholders? Greenwich LifeSciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (0.44%), Renaissance Technologies LLC (0.40%), Susquehanna International Group LLP (0.29%), HRT Financial LP (0.14%), Jane Street Group LLC (0.14%) and Citigroup Inc. (0.10%). Insiders that own company stock include David Mcwilliams, Frank Joseph Daugherty, Jaye Thompson, Kenneth Hallock and Snehal Patel. View institutional ownership trends. How do I buy shares of Greenwich LifeSciences? Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Greenwich LifeSciences' stock price today? One share of GLSI stock can currently be purchased for approximately $10.97. How much money does Greenwich LifeSciences make? Greenwich LifeSciences (NASDAQ:GLSI) has a market capitalization of $140.96 million. How can I contact Greenwich LifeSciences? The official website for the company is www.greenwichlifesciences.com. The company can be reached via phone at 832-819-3232 or via email at info@greenwichlifesciences.com. This page (NASDAQ:GLSI) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.